ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Tuesday, November 19, 2024

11:00AM-12:30PM: Abstract Number: 2664

BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

11:00AM-12:30PM: Abstract Number: 2661

Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

11:00AM-12:30PM: Abstract Number: 2673

Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis

Abstracts: RA – Treatment II: Refining Use of Established Therapies

11:00AM-12:30PM: Abstract Number: 2689

Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated II

11:00AM-12:30PM: Abstract Number: 2660

Developing Predictive Models for the Diagnosis of VEXAS Syndrome

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

11:00AM-12:30PM: Abstract Number: 2668

Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

11:00AM-12:30PM: Abstract Number: 2686

Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

11:00AM-12:30PM: Abstract Number: 2669

Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

11:00AM-12:30PM: Abstract Number: 2678

History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2688

HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

11:00AM-12:30PM: Abstract Number: 2662

In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

11:00AM-12:30PM: Abstract Number: 2677

N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2683

Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

11:00AM-12:30PM: Abstract Number: 2679

Predictors of Fracture in SLE: A Longitudinal Cohort Study

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2672

Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial

Abstracts: RA – Treatment II: Refining Use of Established Therapies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].